{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+%28Novantrone%29&page=7", "query": { "intervention": "Mitoxantrone (Novantrone)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 177, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+%28Novantrone%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+%28Novantrone%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T17:47:08.718Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00385827", "title": "A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer, Prostate" ], "interventions": [ { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Siltuximab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 106, "start_date": "2006-11", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2014-08-20", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 11, "location_summary": "Norwalk, Connecticut • Port Saint Lucie, Florida • Atlanta, Georgia + 8 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00385827" }, { "nct_id": "NCT00208975", "title": "Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2002-07", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00208975" }, { "nct_id": "NCT00136084", "title": "Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myelocytic, Acute" ], "interventions": [ { "name": "Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone", "type": "DRUG" }, { "name": "Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 238, "start_date": "2002-08", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-12-05", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 8, "location_summary": "Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136084" }, { "nct_id": "NCT00410423", "title": "Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Acute Leukemia", "Refractory Acute Leukemia" ], "interventions": [ { "name": "Bortezomib with mitoxantrone, etoposide and cytarabine", "type": "DRUG" }, { "name": "Bortezomib 1.0mg/m^2", "type": "DRUG" }, { "name": "Bortezomib 1.3mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2006-01", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00410423" }, { "nct_id": "NCT00002474", "title": "Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "FEMALE", "summary": "Up to 64 Years · Female only" }, "enrollment_count": null, "start_date": "1991-02", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002474" }, { "nct_id": "NCT02518750", "title": "Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoma, Non-Hodgkin's", "Leukemia, T-Cell", "Leukemia, B-Cell" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Liposomal vincristine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Peg-asparaginase", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Intrathecal Triples", "type": "DRUG" }, { "name": "High-dose methotrexate", "type": "DRUG" }, { "name": "6-Mercaptopurine", "type": "DRUG" }, { "name": "High-dose cytarabine", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3, "start_date": "2016-11-23", "completion_date": "2018-03-11", "has_results": true, "last_update_posted_date": "2019-04-03", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02518750" }, { "nct_id": "NCT02419755", "title": "Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mixed Lineage Acute Leukemia", "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Peg-L-Asparaginase", "type": "DRUG" }, { "name": "Erwinia L-Asparaginase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2015-04-14", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2018-03-07", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419755" }, { "nct_id": "NCT00107354", "title": "Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": null, "start_date": "1998-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-20", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107354" }, { "nct_id": "NCT01701375", "title": "A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Leukemia", "Refractory Acute Leukemia", "High-Risk Myelodysplasia" ], "interventions": [ { "name": "PD 0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-09-09", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701375" }, { "nct_id": "NCT02632708", "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed Acute Myeloid Leukemia (AML)", "Untreated AML", "AML Arising From Myelodysplastic Syndrome (MDS)", "AML Arising From Antecedent Hematologic Disorder (AHD)", "AML Arising After Exposure to Genotoxic Injury" ], "interventions": [ { "name": "AG-120", "type": "DRUG" }, { "name": "AG-221", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-12-31", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-09T17:47:08.718Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02632708" } ] }